Gastric cancer (GC) is one of the most common malignancies worldwide. Most patients are
diagnosed at advanced stages due to the subtle symptoms of earlier disease and the low …

Tumours display an astonishing variation in the spatial distribution, composition and
activation state of immune cells, which impacts their progression and response to …

There is an urgent need for first-line treatment options for patients with human epidermal
growth factor receptor 2 (HER2)-negative, locally advanced unresectable or metastatic …

The sixth edition of the Japanese Gastric Cancer Treatment Guidelines was completed in
July 2021, incorporating new evidence that emerged after publication of the previous …

Background Zolbetuximab, a monoclonal antibody targeting claudin-18 isoform 2 (CLDN18.
2), has shown efficacy in patients with CLDN18. 2-positive, human epidermal growth factor …

Cancers originating in the esophagus or esophagogastric junction constitute a major global
health problem. Esophageal cancers are histologically classified as squamous cell …

More than 1 million (1 089 103) new cases of gastric cancer were estimated globally in
2020, resulting in 768 793 deaths. 1 These burden estimates will continue to increase due to …

Gastric cancer is the third leading cause of cancer-related deaths worldwide. Over 95% of
gastric cancers are adenocarcinomas, which are typically classified based on anatomic …

Human epidermal growth factor receptor 2 (HER2, also known as ERBB2) amplification or
overexpression occurs in approximately 20% of advanced gastric or gastro-oesophageal …

Background The additive or synergistic sustained antitumour effect of immune checkpoint
inhibitors in combination with oxaliplatin-based chemotherapy has previously been …